Unique ID issued by UMIN | UMIN000021015 |
---|---|
Receipt number | R000024254 |
Scientific Title | Verifying the early diagnostic method of adenovirus-induced hemorrhagic cystitis after allogeneic hematopoietic stem cells transplantation |
Date of disclosure of the study information | 2016/02/14 |
Last modified on | 2019/03/28 20:54:48 |
Verifying the early diagnostic method of adenovirus-induced hemorrhagic cystitis after allogeneic hematopoietic stem cells transplantation
Early diagnosis of adenovirus-induced hemorrhagic cystitis after allo-HSCT
Verifying the early diagnostic method of adenovirus-induced hemorrhagic cystitis after allogeneic hematopoietic stem cells transplantation
Early diagnosis of adenovirus-induced hemorrhagic cystitis after allo-HSCT
Japan |
adenovirus-induced hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation
Hematology and clinical oncology | Infectious disease |
Others
NO
This study will prospectively examine urinary adenoviral DNA over time to inspect an early diagnostic method of adenovirus-induced hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation
Efficacy
The efficacy of quantifying urinary adenoviral DNA for diagnosis of adenovirus-induced hemorrhagic cystitis
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Diagnosis
Gene |
Urinary adenoviral DNA is quantified in accordance with the schedule below.
1. Before the start of conditioning chemotherapy
2. Every two weeks after allogeneic hematopoietic stem cell transplantation
3. In case hemorrhagic cystitis has been developed, every week until improvement
4. At the outpatient clinic, once a month until one year post HSCT
16 | years-old | <= |
Not applicable |
Male and Female
1. Patients who have a plan to undergo allogeneic hematopoietic stem cell transplantation
2. Patients who are going to be hospitalized for at least four weeks
3. Patients who agree in writing
1. Patients whom hemorrhagic cystitis has already developed
2. Patients who are recognized as inadaptable for this trial
20
1st name | |
Middle name | |
Last name | Shinji Nakao |
Kanazawa University Hospital
Department of Hematology
13-1, Takara-machi, Kanzawa, Ishikawa
076-234-2275
snakao8205@staff.kanazawa-u.ac.jp
1st name | |
Middle name | |
Last name | Yukio Kondo |
Kanazawa University Hospital
Department of Hematology
13-1, Takara-machi, Kanzawa, Ishikawa
076-234-2275
y-kondo@staff.kanazawa-u.ac.jp
Department of Hematology, Kanazawa University Hospital
Department of Hematology, Kanazawa University Hospital
Self funding
NO
2016 | Year | 02 | Month | 14 | Day |
Unpublished
Terminated
2014 | Year | 02 | Month | 19 | Day |
2013 | Year | 07 | Month | 26 | Day |
2016 | Year | 02 | Month | 15 | Day |
2019 | Year | 03 | Month | 31 | Day |
2016 | Year | 02 | Month | 14 | Day |
2019 | Year | 03 | Month | 28 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024254
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |